This drug also showed significant anti-cancer effects in resistant patients with NSCLC in clinical trials, and has been approved for NSCLC therapy by the NMPA recently.84 The success of osimertinib and almonertinib in overcoming acquired resistance is mainly attributed to their high potency and selectivity against the EGFR T790M mutation. Here, EGFR is linked to non-small cell lung carcinoma.